Descripción
Risk of bias assessment across included randomized controlled trials in the AGA treatment network meta-analysis, evaluated using the Cochrane Risk of Bias tool domains.
FIGURE 6
ChartSource Paper
Hair regrowth treatment efficacy and resistance in androgenetic alopecia: A systematic review and continuous Bayesian network meta-analysis.Cite This Figure
 > Source: Peter R Feldman et al. "Hair regrowth treatment efficacy and resistance in androgenetic alopecia: A syst." *Frontiers in medicine*, 2022. PMID: [36755885](https://pubmed.ncbi.nlm.nih.gov/36755885/)
<figure> <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900126/bin/fmed-09-998623-g006.jpg" alt="Risk of bias assessment across included randomized controlled trials in the AGA treatment network meta-analysis, evaluated using the Cochrane Risk of Bias tool domains." /> <figcaption>FIGURE 6. Risk of bias assessment across included randomized controlled trials in the AGA treatment network meta-analysis, evaluated using the Cochrane Risk of Bias tool domains.<br> Source: Peter R Feldman et al. "Hair regrowth treatment efficacy and resistance in androgenetic alopecia: A syst." <em>Frontiers in medicine</em>, 2022. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/36755885/">36755885</a></figcaption> </figure>
Evidencia relacionada
A
Minoxidil para Alopecia Androgenética
A
Calificación A · 299 estudios
Finasteride para Alopecia Androgenética
A
Calificación A · 206 estudios
Nutrafol para Alopecia Androgenética
A
Calificación A · 3 estudios
Terapia Láser de Baja Intensidad para Alopecia Androgenética
A
Calificación A · 60 estudios
Viviscal para Telogen Effluvium
A
Calificación A · 8 estudios
Viviscal para Adelgazamiento Capilar por Envejecimiento
A
Calificación A · 8 estudios
Nutrafol para Pérdida Capilar de Patrón Femenino
A
Calificación A · 8 estudios
Nutrafol para Pérdida Capilar por Estrés
A
Calificación A · 8 estudios
Dutasteride para Alopecia Androgenética
Calificación A · 99 estudios